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3INTRODUCTION
Free peritoneal tumor cells and peritoneal carcinomatosis
The tumor dissemination starts from the primary tumor and consists
of a multistep process. Firstly, individual or clusters of tumor cells
must detach from the primary tumor mass and gain access to the
peritoneal cavity.
The detachment could occur by several mechanisms and the most
frequent one in gastrointestinal cancers is spontaneous exfoliation of
tumor cells from cancers that have invaded the serosa. This process
4could be mediated by the down-regulation of intercellular adhesion
molecules on the tumor cell surface, for example E-cadherin.
Cadherins are transmembrane glycoproteins with an extracellular
part, a membrane-spanning domain and a cytoplasmatic tail. They
form a family with currently about 80 members, but information
related to peritoneal carcinomatosis is now restricted to the
subfamily of classical (or type I) cadherins. In epithelial tumors the
expression or the function of E-cadherin is downregulated, and this
has also been confirmed for colorectal, gastric and ovarian cancers
with peritoneal carcinomatosis. The presence of viable tumor cells in
the peritoneal cavity could also occur by iatrogenic or spontaneous
perforation of the primary cancer or from transacted lymphatics and
blood vessels during the course of surgical resection. Once the cancer
cells are seeded in the peritoneal cavity they spread to different
anatomical regions of the abdomen governed by 3 basic forces:
gravity, peristaltic movement of the gastrointestinal tract, and
negative pressure exerted by diaphragm muscle movements. The
successive localization of intraperitoneal dissemination depends on
the biology not only of free cancer cells and but also of the tissue that
will harbor the metastatic implantation. The process takes place
5through 2 routes denominated transmesothelial and translymphatic
metastasis. According to the first mechanism the free cancer cells
directly attach on distant mesothelium and this process is mediated
by adhesion molecules such as CD44, lymphocyte homing molecules,
members of integrin superfamily, the selectins and a variety of other
leukocyte associated adhesion molecules.
In the successive step, the production of cytokines (interleukins, EGF,
HGF, VEGF-C) induces the contraction of mesothelial cells exposing
the submesothelial basement membrane. Yonemura et al
investigated this phenomena using an animal model and a gastric cell
6line, MKN-45-P. Intraperitoneal inoculation of MKN-45-P resulted in
mesothelial contraction and eventual exfoliation. However, Jayne et
al postulated another mechanism underlying tumor-mesothelial
invasion. They used a three dimensional in vitro model of the human
peritoneum, and found that colorectal cancer cell lines adhered
rapidly to the outer mesothelial monolayer. Closer inspection of
points of mesothelial invasion was frequently accompanied by
changes in mesothelial cell morphology suggestive of apoptosis,
confirmed by DNA fragmentation assays and immunohistochemistry.
After attaching to the peritoneum and penetrating the mesothelial
barrier, the tumor cells adhere to the submesothelial connective
tissue through the interaction of integrins. These molecules are
receptors for components of the basement membrane of cancer
cells. Kawamura et al studied the expression of various metastasis
related genes (integrins subunits, motility factors, proteases, growth
factors) between 2 gastric cancer cell lines: MKN-45 and MKN-45-P.
The latter was characterized by its high peritoneal metastatic
potential. Integrin α2 and α3 subunits were significantly elevated in
MKN-45-P compared to MKN-45. These α integrins dimerize with β1-
subunits to form adhesion molecules for various basement
7membrane proteins, including fibronectin, laminin, and collagen IV,
which are secreted by human mesothelium. The invasion of
subperitoneal tissue requires the degradation of the peritoneal blood
barrier by motility factors and matrix proteinases. The matrix
metalloproteinases (MMPs) may play a central role in stromal
invasion. Yonemura et al studied the role of MMP-7 in a mouse
model of peritoneal carcinomatosis. Specific antisense
oligonucleotides inhibited the expression of MMP-7 by the highly
metastatic gastric cell line MKN-45P, and suppressed invasion
without modifying cell proliferation. Moreover, the survival of MKN-
45-P bearing mice, which had been pre-treated with antisense
oligonucleotides, was significantly better than control mice. Other
potential mediators of stromal degradation are the urokinase
plasminogen activating system and the protease inhibitor Bikunin
(bik). Subsequently to invasion of the subperitoneal space in the
vicinity of capillaries, the cancer cells trigger their proliferation
through autocrine and paracrine loops by production of growth
factors from cancer cells or stromal cells. Davies et al showed that
epidermal growth factor (EGF) enhanced the invasive potential of
mammary carcinoma cells when injected into the peritoneal cavities
8of rats and that this growth promoting effect was due to the
production of EGF by the peritoneal host tissue. The next step in the
peritoneal dissemination process is the neoangiogenesis in the
subperitoneal space which is mediated by the production of VEGF-A
and VEGF-C. Besides the transmesothelial route, peritoneal cancer
dissemination could occur by another mechanism denominated the
translymphatic process. According to this theory the peritoneal free
cancer cells gain access to the subperitoneal lymphatic spaces
through lymphatic stomata. Anatomical regions in the peritoneal
cavity with a high density of lymphatic stomata are the greater
omentum, appendices epiploicae of the colon, inferior surface of the
diaphragm, falciform ligament, Douglas pouch and small bowel
mesentery. These locations are characterized by the presence of
another lymphatic structure which is involved in the translymphatic
peritoneal dissemination of free cancer cells, namely the milky spots.
Milky spots are very small structures, in contact with the peritoneal
membrane, devoid of capsule and consisting of macrophages,
lymphocytes and a few plasma cells supported by blood and
lymphatic vessels. The exact role of these particular organs is still not
clear, but they are similar to lymphatic structures and it is clear that
9they play a role in peritoneal cancer dissemination. Lymphatic
stomata are found in the milky spots and peritoneal macrophages
mobilize into the peritoneal cavity through the lymphatic orifices. The
peritoneum layering the Douglas pouch, for example, is rich in
subperitoneal lymphatic vessels and milky spots. The intraperitoneal
fluid containing free cancer cells, once reaching the pelvic
subperitoneal lymphatics, goes toward the rectum and finally flows
into the lymph nodes around the iliac artery. On the other hand the
peritoneum covering the liver, and the serosal surface of small bowel
and spleen are devoid of lymphatic stomata as well as milky spots
and thus are involved in peritoneal dissemination of cancer cells only
in the late stage of peritoneal carcinomatosis. While the mechanism
of peritoneal dissemination in pseudomyxoma peritonei is
characterized by the translymphatic process, the dissemination of
gastric and colon cancer is characterized by both translymphatic and
transmesothelial processes. Pseudomyxoma peritonei is
characterized by the accumulation of abundant gelatinous mucin
within the peritoneal cavity and diffuse mucinous implants on the
peritoneal surface and omentum. The major component of the
lesions is mucinous material while neoplastic epithelial cells are
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extremely scanty. In the past there was a lack of consensus about the
site of origin of this clinical condition, especially in female patients.
There were 3 main hypotheses: (1) metastasis from the ovary to the
appendix; (2) metastasis from the appendix to the ovary, or (3) an
independent origin of the tumor. In exceptionally rare cases other
sites have been reported to be the primary sites, such as the colon,
common bile duct, pancreas and breast. There is a growing body of
evidence, based on morphological, immunohistochemical and genetic
studies, suggesting that the primary site of origin is the appendix in
majority of the cases. The most popular model explaining tumor
progression advocates that an initial neoplastic process (such as a
mucinous adenoma) produces mucin continuously inside the
appendiceal lumen, leading to obstruction and distension of this
structure. The appendix suffers rupture and the mucin material
disseminates inside the peritoneal cavity guided by 3 mechanical
forces: gravity, hydrostatic pressure exerted by respiratory
movements of the diaphragmatic muscle and peristaltic movements
of the bowel. The accumulation and deposition of the neoplastic
material inside the peritoneal cavity at different locations will be
conditioned by the translymphatic model of tumor dissemination, as
11
mentioned above. The biological course is indolent and progressive
and leads the patient to death as a consequence of intestinal
obstruction, unless adequately treated. CDX-2 is the product of the
caudal-type homeobox gene, which encodes a transcription factor
that plays a role as a regulatory protein in proliferation and
differentiation of intestinal epithelial cells. CDX-2 expression is
uniformly found in almost all cases of colorectal and duodenal
adenocarcinomas and appendiceal adenocarcinoma, whereas
expression is heterogeneous in adenocarcinomas of gastric, gastro-
oesophageal and pancreatobiliary origin. Nonaka et al reported in a
series of 42 case of pseudomyxoma peritonei that all cases of
peritoneal lesions, showed diffuse and strong immunoreactivity for
CDX-2 in a uniform nuclear staining pattern. In a successive
evaluation of this marker in the same series of patients, it was shown
that immunoexpression was significantly correlated with overall
survival by univariate analysis. Mucins are high-molecular-weight
glycoproteins, present at the interface between many epithelial and
extracellular environments and synthesized by a broad range of
epithelial tissues. Genes coding for the protein components of mucin
are designated as MUCs. Currently 14 mucin-type glycoproteins have
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been assigned to the MUC gene family. Mucins are subdivided into
membraneassociated and secreted forms, the former represented by
MUC-1 and the latter represented by MUC-2 and MUC- 5AC. MUC-2
is specifically expressed in goblet cells of the small bowel and colon,
while MUC-5AC is generally expressed in the stomach and respiratory
tracts. The vast majority of mucinous epithelial neoplasms of the
appendix coexpress both MUC-2 and MUC-5AC, while mucinous
neoplasms of the ovary express only MUC-5AC but not MUC-2.
Interestingly, cases of classic pseudomyxoma peritonei show the
intestinal⁄appendiceal pattern (MUC-2+ and MUC-5AC+), as do
appendiceal mucinous neoplasms, whereas cases of peritoneal
implants or pseudomyxoma ovarii associated with primary ovarian
mucinous neoplasms show the ovarian pattern (MUC-2- and MUC-
5AC+), just as ovarian mucinous neoplasms do. These findings
support the notion that pseudomyxoma peritonei is a disease
resulting from the accumulation of extracellular secretory-type
mucin, particularly related to MUC-2 overexpression by neoplastic
cells, thereby rendering MUC-2 expression a potential molecular
target to inhibit the progression of the disease.
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Peritoneal carcinomatosis from gastric cancer
In the United States 20 to 30% of patients with gastric cancer being
explored for potentially curative resection will be found to have
peritoneal seeding at the time of surgical exploration. Current
standard treatment is systemic chemotherapy which may delay onset
of symptoms but is not curative. The median survival of these
patients is 5 months with virtually no long-term survivors. Yoo and
colleagues reviewed 2328 patients with gastric cancer who
underwent curative resection with at least 5-years follow-up.
Documented evidence of relapse of the disease was found in 508
patients. Isolated peritoneal recurrence was noted in 34% of patients
who relapsed. Hematogenous recurrence occurred in 26% and local-
regional persistence of the tumor was seen in 19%. Two or more sites
of recurrence were documented in the remaining patients. Serosal
invasion and lymph node metastasis were risk factors of relapse in all
patterns of recurrence. This high incidence of peritoneal
carcinomatosis following curative resections is shared by others, with
an average incidence between 20% and 50%. These data show that in
an impressive number of patients the recurrence is isolated within
the peritoneal cavity. It also suggests that if an effective treatment
14
could be targeted toward peritoneal dissemination, at least a third of
the patients with advanced gastric cancer could experience a better
outcome. Systemic chemotherapy for gastric patients presenting with
peritoneal seeding at the time of abdominal exploration or as a
manifestation of disease recurrence after a curative surgery is
uniformly disappointing. Preusser and colleagues published a
response rate for advanced gastric cancer of 50%; nevertheless
patients with peritoneal dissemination obtained the worst response.
Ajani and colleagues, treated patients prior to gastrectomy. At
exploration, peritoneal carcinomatosis was the most common cause
of failure of intensive neoadjuvant chemotherapeutic treatment.
Also, radiation showed limited results in this situation and is
expected to cause significant morbidity when applied to such a large
field.
Peritoneal carcinomatosis from colorectal cancer
Despite advances for early diagnosis of colorectal cancer, peritoneal
carcinomatosis persists as a major problem. Peritoneal implants are
present in 10% of patients with colorectal cancer at the time of
diagnosis and are the second cause of death after liver metastasis. In
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contrast to the other two main sites of colorectal cancer metastasis,
liver and lymph nodes, peritoneal seeding is considered a condition
uniformly lethal with no perspective of cure. From a database of
3019 colorectal cancer patients, Jayne and colleagues identified 349
patients with peritoneal carcinomatosis. The median survival of this
group was 7 months. Unfortunately this recent data showed no
improvement in the survival of these patients if compared with the
first study of the natural history of peritoneal carcinomatosis
published 13 years before by Chu et al. Also, a European multicenter
trial (EVOCAPE 1) evaluated prospectively 118 patients with
peritoneal carcinomatosis arising from colorectal cancer. The mean
survival of those patients was 6.9 months.
Peritoneal wash cytology
In the majority of reports the peritoneal washing is performed
immediately after the laparotomy in the absence of ascites, once
achieved a complete hemostasis before the incision into the
peritoneum to prevent contamination from leukocytes. One hundred
mL of physiologic saline at 37°C is injected into the Douglas cavity, as
16
recommended by the second edition of the Japanese Classification of
Gastric Carcinoma, and after gentle stirring the fluid is aspirated.
All samples are immediately centrifuged (1500 rpm for 10 min) and
the precipitates are smeared. The precipitates are promptly fixed
with 95% alcohol for Papanicolaou staining, fixed with 100% ethanol
for periodic acid-Schiff (PAS) staining, and dried with a drier for May-
Giemsa staining. The fixed samples are stained by the staining
procedures corresponding to the different fixation methods. The
slides are examined by light microscopy by experienced
cytopathologists.
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The result of the cytological examination include 3 different
outcomes: CY0, benign/indeterminate cells on peritoneal cytology;
CY1, cancer cells on peritoneal cytology; CYX, peritoneal cytology not
performed. The CY0 group in cytological diagnosis comprise
“suspicious of malignancy”. Conventional cytological examination is
often criticized for its relatively low sensitivity. The overall positive
cytology rate depends on the cohort of patients being studied,
ranging from 14% to 70%. Bando demonstrated a positive cytology
rate of 24%. This series of 1 297 patients included cases with
advanced gastric cancer (296 patients with peritoneal metastasis and
77 patients with T4 tumors). Ribeiro reported a positive cytology rate
of 41% incidence in a series of 49 patients with both localized and
metastatic gastric cancer. Literature reports demonstrated that
cytology is strictly related to the extent of the tumor, and with the
involvement locoregional lymph-nodes, according with the theory
Papanicolaou Stain
(400X)
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that cancer cells can directly exfoliate and desquamated from
serosa into the peritoneum adjacent to the tumour, or alternatively,
seed into the peritoneal space through mesenteric lymphatics
through so-called “gaps” in association with milky spots. When only
potentially curative resections are included, in fact, the rate of FPTC
varies from 4.4-11%, and ranges from 22-30% in gastric carcinoma
involving the serosa. The Dutch Gastric Cancer Trial demonstrated
positive cytology in only 7.1% of all patients with gastric cancer and in
12% of those with serosal invasion. These results indicate that the
conventional cytological examination lacks sensitivity for the
detection of residual cancer cells and prediction of peritoneal spread,
as evident from the fact that several intraperitoneal recurrences can
be observed among patients with negative cytology results and that
patients with macroscopically evident peritoneal metastasis can
show negative cytology results. Wang et al. showed that only 67% of
patients (8/12) with macroscopically evident peritoneal metastasis
showed a positive peritoneal cytology. In order to improve sensitivity
of conventional cytology Homma et al. performed peritoneal wash
cytology in four different cavities: the left subphrenic cavity, right
subhepatic cavity, Douglas’ pouch, and inside the omental bursa,
19
differently form the Japanese Classification of Gastric Cancer
recommendation to perform peritoneal wash cytology only in
Douglas’ pouch. They found that peritoneal wash cytology in
multiple cavities allows to increase sensitivity of cytology, showing
that eleven (17.7%) patients who had negative peritoneal wash
cytology in Douglas’ pouch, were positive in the other cavities.
Ribeiro, in order to improve sensibility and sensitivity of peritoneal
wash cytology, demonstrated also that the number and the
arrangement of FPTC are an important parameter of cytological
evaluation. In fact, the survival rate appears to change if FPTC are,
clustered, isolated, or clustered-plus-isolated type. The reliability of
morphologic diagnosis in cytology is limited, and the differential
diagnosis between benign reactive mesothelial cells and well-
differentiated carcinoma cells is often difficult. Therefore, a more
sensitive method for detecting free cancer cells in the peritoneal
cavity is needed. In fact, the peritoneal wash cytology has a
sensitivity of 90% to 96.7% and nearly 100% specificity in the
diagnosis of FPTC. False-positive peritoneal lavage cytology has been
recognized by some authors, with a rate of 4.5% to 5%, probably
secondary to reactive mesothelial cells.
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Other  techniques
In order to diminish the false-positive and -negative rates, several
authors have used immunocytochemistry and molecular biology
techniques, including reverse transcriptase–polymerase chain
reaction for carcinoembryonic antigen messenger RNA. Some groups
have used immunocytochemical analysis to detect cancer cells in
peritoneal lavage. This technique consists in using a panel of different
monoclonal antibodies (MoAbs), (B72.3, AR3, BD5, HEA 125, and
monoclonal CEA clone 11-7) directed to gastric cancer-associated
antigens. MoAbs allow to improve the detection rate of FPTC in
peritoneal washing in a percentage comprises between 5% and 15%
compared to standard cytology. Nevertheless, the antigens utilized as
marker of FPTC at the immunocytology are not cancer specific, and
they can be expressed and produced also by non-tumoral cell during
inflammatory response (frequently reactive mesothelial cells).
Therefore, in order to avoid false positive results of FPTC,
immunocytochemical results should be compared to cytological
features of malignancy, or utilized as a confirmation of a suspicious
feature at the standard cytology. In a recent study we showed the
results of PWC in patients underwent gastric resection for gastric
21
carcinoma, demonstrating that the use of immunocytology was
limited to dubious or suspicious glass slides. The dosage of
carcinoembryonic antigen (CEA) levels in peritoneal washings was
proposed to detect microscopic residual tumor in 1989 by Asao et al.
who later found that the 2-year survival rates after curative
operation for the patients with and without elevation of CEA levels
were 21% (19 patients) and 100% (66 patients), respectively
(P<0.001). Subsequently other authors investigated other tumor
markers: in 1999 Bold et al. showed how elevated peritoneal levels of
cancer antigen 125 (CA 125) in the peritoneal washing significantly
predicted peritoneal recurrence in patients who underwent curative
gastrectomy, but that was not valid for peritoneal levels of CEA .
Some other papers followed during the next years most of them
showing how peritoneal CEA was more sensitive (positivity rate
~40%) than cytology and that high levels of CEA were related to a
greater extension of the disease, to a higher risk of peritoneal
carcinomatosis and to a worse prognosis. All these studies used
several different methods for assessing the tumor markers dosage in
the peritoneal fluid and used even very different cut-off values. The
peritoneal dosage of tumor markers was soon abandoned by
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researchers in favour of the more reliable and more standardized
reverse transcriptase polymerase chain reaction technique. The high
sensitivity of reverse transcriptase-polymerase chain reaction (RT-
PCR) techniques was already found to allow diagnosis of
micrometastases based on tissue-specific mRNA expression in tumor
cells in peripheral blood, bone marrow and lymph nodes. In 1997 a
Japanese group first proposed the use of RT-PCR for the detection of
free peritoneal tumor cells from perioperative peritoneal washings
from patients affected with gastric cancer. Briefly in this technique
peritoneal lavage samples are centrifuged and the cell pellets are
subjected to RNA isolation and amplification. CEA mRNA was firstly
used for RT-PCR based molecular detection of peritoneal free tumor
cells; later other Authors reported about some gastric cancer cells
that do not express CEA mRNA and additional markers were
introduced such as cytokeratins, trypsinogen, telomerase, matrix
metalloproteinase-7 (MMP-7), dopa decarboxylase, L-3 phophoserine
phosphatise. In all studies a greater sensitivity of RT-PCR was
reported in comparison with cytology, the global positivity rate
ranged between 40% and 70%, being for patients with T1, T2, T3 and
T4 stage disease respectively about 10%, 30%, 65% and 90%. Most of
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the studies reported how the positive RT-PCR test was significantly
and independently related to an increased risk for peritoneal
carcinomatosis and to a worse survival. In the largest series reported
in literature all patients who presented peritoneal carcinomatosis
during the follow up period were positive at time of surgery for RT-
PCR on peritoneal washes and omentum while only about 30% of
them were positive also for conventional cytology. Some criticism
have been moved to this technique, in fact some Authors believe that
the expression of some genes used for the identification of tumor
cells may be present in inflammatory cells as well, resulting RT-PCR in
a high sensitivity and low specificity test. Molecular diagnostic
technique has been used also for the prediction of the effects of
chemotherapy: in one study the prognosis of patients who showed a
change in the result of RT-PCR on the peritoneal washing from
positive to negative was significantly improved compared to those
who remained positive after chemotherapy. Some problems about
the optimization of these techniques still have to be debated for
example the possibility of high rate of false positive diagnosis at RT-
PCR. This can be due to an illegitimate expression of marker genes in
noncancerous cells or to a (too) high sensitivity of the technique that
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can even discover markers mRNA from a very small, clinically
insignificant, number of cells. Nevertheless in some Japanese
Institutions RT-PCR is already used in the clinical practice: patients
with negative cytology and positive RT-PCR at preoperative staging
laparoscopy are treated with a short-term intraperitoneal
chemotherapy. Molecular diagnostic techniques are, however, time-
consuming, relatively laborious and more expensive compared with
conventional cytodiagnostic methods; there are actually many
different methods of molecular diagnosis among institutions, and this
causes delay in his routine clinical application. Since 2006, the
Japanese Government included the molecular biology assay diagnosis
of body fluids in the public health insurance program for patients
with solid tumors, facilitating the introduction into clinical practice of
genetic diagnostic techniques for peritoneal lavage from patients
with gastric cancer, but, at present, only University hospitals and
large cancer centers use this techniques.
Aim of the study
In the attempt to further demonstrate the diagnostic/prognostic
value of the detection of epithelial-tumor markers in the peritoneal
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washes and to rule out the possibility of false positive results using
molecular-based techniques alone, in this study we combined the
qRT-PCR analysis with an immunomagnetic enrichment followed by
immunofluorescence (IF) analysis, for enhancing the specificity of
detection of the free peritoneal tumor cells (FPTCs). To this aim, the
peritoneal washes were directed to a procedure commonly used for
detection of circulating tumor cells CTC from blood samples (20). To
detect the disseminated epithelial cells, we used monoclonal
antibody against the pan-epithelial marker EpCAM/CD326 and to
ascertain their tumor origin we used polyclonal antibodies against
the carcinoembryonic antigen (CEA). In this setting, IF microscopy
allowed the morphological assessment and unequivocal identification
of the FPTCs as well as validation of the molecular analysis. This
combined use of immunomagnetic enrichment, IF analysis and real-
time qRT-PCR, showing a greater sensibility respect to conventional
cytology, was able to permit the detection of free peritoneal tumor
cells in both gastric and colorectal cancer and to determine their
prognostic value for survival.
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MATERIAL AND METHODS
Patients and Surgery
All patients were extensively informed and gave written consent for
the investigations. The study was approved by the local ethical
commission. Twenty-seven gastric and 48 colorectal patients with
cancer who underwent surgery between December 2008 and
December 2009 at the A Unit of Surgery of Sant’Andrea Hospital
were investigated. Patients with distal extraperitoneal rectum cancer
were excluded from the study. Preoperative chemotherapy or
radiation therapy was not performed in this series.
Gastric cancer patients (GC) underwent subtotal gastrectomy in 15
cases, total gastrectomy in 8 cases and palliative surgery in 4 cases.
Colorectal cancer patients (CRC) underwent right colectomy in 23
cases, left colectomy in 10 cases, anterior resection in 14 cases and
palliative surgery in 1 case. All patients underwent open surgery. A
control group comprised 6 patients with a variety of non-carcinoma
diseases: benign uterus tumor, cholecystolithiasis and colic adenoma.
Follow-up data were obtained for a median observation time of 17
months (range 1-27 months).
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Samples
Immediately after a midline abdominal incision had been made and
before manipulation of the tumor, peritoneal washing was
performed. Intraoperatively, 250 mL of saline were instilled into the
abdominal cavity over the tumor site and at least 150 mL were
reaspirated. Twenty mL were sent for cytological examination which
was performed after Papanicolaou and Giemsa stainings. The slides
were examined by light microscopy by experienced cytologists
unaware of the clinical findings. Patients with suspicious
morphological evidence of malignancy by microscopy were included
in the positive cytology group.
RNA extraction and cDNA synthesis
Each peritoneal wash sample was centrifuged at 1200 rpm for 10’
and total RNA was extracted using the TRIzol method (Invitrogen,
Carlsbad, CA, USA) according to the manufacture’s procedure. Briefly
cells were homogenized in 1 mL TRIzol reagent and RNA was
extracted by incubation and centrifugation in 0,2 mL CHCl3. RNA was
precipitated from aqueous phase by 0,5 mL of isopropanol. RNA
pellet was washed in 75% ethanol and eluted with 0,1%
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diethylpyrocarbonate (DEPC)-treated water. Total RNA quantity,
purity and absence of ribonuclease digestion were assessed by
measuring the optical density ratio 260/280 nm. Total RNA samples
were stored at -80°C. After denaturation in DEPC-treated water at
70°C for 10 min, 1 µg of total RNA was used to cDNA synthesis using
cDNA synthesis mix (Bio-Rad Laboratories, Hercules, CA, USA).
Real-time PCR primer design
Gene sequences were obtained from the NCBI database.
Oligonucleotide primers for CEA and CK20 target genes and GAPDH
housekeeping gene were chosen with the assistance of the Beacon
Designer 7.0 computer program (Bio-Rad Laboratories). The primers
sequences used throughout this study are described in the Table 1.
For each primer pair, we performed no-template control and no-
reverse-transcriptase control (RT negative) assays, which produced
negligible signals (usually >45 in threshold cycle (Ct) value),
suggesting that primer dimer formation and genomic DNA
contamination effects were negligible. Oligonucleotide primers were
purchased from Invitrogen.
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Table 1. Primers sequence and amplification efficiency.
Name Primer Forward Primer Reverse Eff.%
GAPDH 5’CATCAGCAATGCCTCCTGCAC3’ 5’GTCATGAGTCCTTCCACGATACCAA3’ 99.7
CEA 5’AGGACAGAGCAGACAGCAGAG3’ 5’GGTTCCAGAAGGTTAGAAGTGAGG3’ 94.4
CK20 5’TGCTACTTACCGCCGCCTTC3’ 5’CCTTGCCATCCACTACTTCTTGC3’ 103
PCR amplification
Real-time PCR was performed using the iCycler Real-Time Detection
System (iQ5 Bio-Rad) with optimized PCR conditions. The reaction
was carried out in a 96-well plate using iQ SYBER Green Supermix 2X
(Bio-Rad) adding each forward and reverse primers and 1 µl of
diluted template cDNA to a final reaction volume of 15 µl. All assays
included a negative control and were replicated three times. The
relative expression of GAPDH was used for standardizing the
reaction. The thermal cycling conditions comprised an initial
denaturation step at 95°C for 3 minutes, followed by 45 cycles at
95°C for 10 seconds and 60°C for 30 seconds.
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Data analyses
Real-time quantitation was performed by using SYBR Green dye as
fluorescent signal, with the help of the iCycler IQ optical system
software version 3.0a (Bio-Rad), according to the manufacturer’s
manual. Quantitative values are obtained from the Ct number at
which, the increase in signal associated with exponential growth of
PCR products, starts to be detected. Target genes (CEA, CK20)
amplification was compared with simultaneous amplification of an
endogenous reference gene (GAPDH) and each sample was
normalized on the basis of its GAPDH content. The target genes CEA
and CK20 were tested for expression in tenfold serial dilutions (106-
100) of cancer cell lines from colon (HT29, Caco2) and gastric (AGS)
carcinoma. Normal human fibroblast cell line from colon (CCD18) and
primary culture of human fibroblasts from skin were used as negative
controls. For data analysis, receiver-operating characteristic (ROC)
curves were used to compare the accuracies of CEA/GAPDH,
CK20/GAPDH ratio and determine the cut off value by plotting
sensitivity/specificity pairs for the two mRNA ratio. The clinical value
of CEA and CK20 detection was assessed based on the diagnostic data
from patients with positive cytology made at laparoscopy and from
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patients of the control group. The cut off value for CEA and CK20 was
defined as 0.66 (gene target/GAPDH ratio). The sensitivity and
specificity obtained at the determined cut off were 77% and 100%
respectively for the CEA/GAPDH ratio and 100% and 93% for the
CK20/GAPDH ratio.
Immunomagnetic enrichment for epithelial cells.
From each patient, 40 mL of peritoneal wash were collected in EDTA
(50 µm). Samples were centrifuged at 1300 rpm for 6 min at 25°C and
resuspended for magnetic labeling in 80 µL of MACS® separation
buffer (Miltenyi Biotec, Bergisch Gladbach, Germany).
Immunomagnetic depletion using anti-CD45 microbeads (Miltenyi
Biotec) was performed according to the manufacturer’s instructions
to enrich for FPTCs (Figure 1A). Briefly, MS separation columns
(MACS®, Miltenyi Biotec) had been equilibrated with 0,5 mL of
MACS® separation buffer and the microbeads labeled cells were
subjected to magnetic field trough the column passage. The CD45
negative cells were washed off from the column with 1,5 mL of
MACS® separation buffer (Figure 1B) and centrifuged at 1300 rpm for
6 min at 25°C.
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Immunofluorescence
CD45 negative cells were incubated with anti-CD326/EpCAM-FITC
monoclonal Ab (1:10 in MACS® separation buffer) for 15 min at 4°C
(Figure 1C). Cells were then washed, centrifuged at 1300 rpm for 6
min at 25°C and the pellet was resuspended in 10 µL of cell solution
and spotted on 8 wells diagnostic slides (Menzel-Glaser,
Braunschweig, Germany), left to dry and fixed with acetone for 8 min
at -20°C. Cells were then incubated with anti-CEA polyclonal
antibodies (Zymed, Invitrogen, Carlsbad, CA, USA) (1:100 in MACS®
separation buffer) for 1 h at 25°C. After appropriate washing, the
primary antibodies were visualized using goat anti-rabbit IgG-Texas
Red (1:400 in MACS® separation buffer) for 30 min at 25°C. Nuclei
were stained with DAPI (1 ng/mL, Sigma Chemicals, St Louis, MO,
USA). Coverslips were finally mounted with mowiol for observation.
Cells were analyzed by conventional fluorescence or by scanning in a
series of 0.5 µm sequential optical sections with an ApoTome System
(Zeiss, Oberkochen, Germany) connected with an Axiovert 200
inverted microscope (Zeiss). Image analysis was performed by the
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Axiovision software (Zeiss). Single optical sections were acquired by a
CCD camera and image analysis was performed by the Axiovision
software (Zeiss).
Statistics
A cross-tabulation analysis of histopathological findings with qRT-PCR
analysis,  immunofluorescence evaluation and cytologic examination
was performed by the chi-square test for trend or Fisher’s exact test.
The analysis of cancer specific survival and time to recurrence rates
was calculated using the Kaplan-Meier method and compared using
the log-rank test. Cox proportional-hazards regression was
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performed to analyze the effect of all variables on survival and
recurrence times.
A p value of 0.05 was considered as statistically significant.
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RESULTS
The application of immunomagnetic enrichment for epithelial cells
and immunofluorescence analysis was performed in peritoneal
lavages obtained from patients affected by gastric or colorectal
cancers and this results were then associated and compared to the
conventional cytology and to the molecular qRT-PCR analysis for the
expression of CEA and CK20 mRNA. For the immunomagnetic
enrichment we used a consolidated method of immunodepletion of
the inflammatory CD45+ cells, which are the major cell population
present in the peritoneal washes. After depletion, the CD45-cells
washed out from the column were immunolabeled for the epithelial
marker CD326/EpCAM and for the tumor marker CEA: cells were then
evaluated by immunofluorescence microscopy to search for the
FPTCs (Figure 1A-C). In our analysis, only cells double positive for
EpCAM and CEA were considered as FPTCs. In addition, careful
observation of the cell nuclei stained by DAPI allowed to evaluate the
cell viability and to exclude apoptotic or necrotic cells from our
analysis (Fig 1D).
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Figure 1. A-C. Immunoenrichment and immunofluorescence methods to detect
free disseminated peritoneal tumor cells (see text). D. Images of EpCAM/CEA
positive FPTCs (yellow) surrounded by epithelial cells positive for EpCAM
(green) or IF double negative inflammatory or mesothelial cells.
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Gastric Carcinoma
Global positivity rate for cytology, IF and qRT-PCR was 15%, 15% and
78% respectively. Cytology was positive in only 4 patients with T4
tumours, which were also characterized by massive peritoneal
carcinomatosis. All these 4 patients were positive qRT-PCR markers
and three of them were positive to the IF too. Interestingly, one
patient with minor peritoneal carcinomatosis was negative at the
cytological examination, but positive at both IF and qRT-PCR analysis.
Table 2 shows the results for IF in gastric carcinoma patients.
Table 2. Correlation between immunofluorescence evaluation, cytologic
examination and histopathological findings in gastric carcinoma.
Factor All
patients
IF
negative
IF
positive
P value
No of patients 27 22
(85.2%)
4 (14.8%)
Age (years)
- mean ±  SD 69.7 ±
12.8
Gender
- Male
- Female
14
13
Histology
(differentiated/undifferentiated)
- G1
- G2
- G3
- G4
2
1
18
6
2
1
18
2
0
0
0
4
0.005*
Depth of invasion
- T1
- T2
- T3
- T4
6
5
8
8
6
5
8
4
0
0
0
4
0.01*
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Stage at primary diagnosis
- I
- II
- III
- IV
7
4
7
9
7
4
7
5
0
0
0
4
0.014*
Cytologic examination
- negative
- positive
23
4
23
1
0
3
0.0014^
The chi-square test for trend showed how the worse grading
(p=0.005), the deeper invasion of the gastric wall (p=0.01), the
advanced stage of disease (p=0.014) and positive cytology (p=0.0014)
are all related to the positivity at IF.
The molecular qRT-PCR method showed a remarkably higher
incidence of positivity: in fact, expression of the markers was over
the cut-off level in all T2 and T4 patients, in 3 out of 6 of the T1
patients and in 5 out of 8 of T3 patients. Moreover, as shown in
Figure 2, there was a clear higher positivity for CEA (70%) respect to
CK20 (41%). The combination of positivity for CEA and CK20 was
observed in 36% of patients.
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The positivity at qRT-PCR was not related to the depth of invasion,
stage of disease and to the IF  positivity but also associated to the
worse grading (p=0.008; table 3).
Figure 2. Expression levels of CEA and CK20 mRNA in control subjects and gastric
cancer patients. The cutoff values of CEA/GAPDH and CK20/GAPDH was 0.66.
The open circles show the alive patients. The gray closed circles show patients
who relapse. The black closed circles show patients who died by tumor-relates
causes.
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Table 3. Relationship between qRT-PCR analysis, immunofluorescence
evaluation and histopathological findings in gastric carcinoma.
Factor All
patients
qRT-PCR
negative
qRT-PCR
positive
P value
No of patients 27 6 (22.2%) 21
(77.8%)
Age (years)
- mean ±  SD 69.7 ±
12.3
Gender
- Male
- Female
14
13
Histology
(differentiated/undifferentiated)
- G1
- G2
- G3
- G4
2
1
18
6
2
0
4
0
0
1
14
6
0.008*
Depth of invasion
- T1
- T2
- T3
- T4
6
5
8
8
3
0
3
0
3
5
5
8
0.098*
Stage at primary diagnosis
- I
- II
- III
- IV
7
4
7
9
2
1
2
1
5
3
5
8
0.43*
Immunofluorescence evaluation
41
- negative
- positive
22
5
5
1
17
4
1^
The Kaplan-Meyer survival analysis showed how the positivity of IF
and qRT-PCR for FPTCs was a statistically significant negative
prognostic factor in both cancer specific overall survival  and disease
free survival rates (Figures 3-6).
Figure 3. Time to recurrence rates by IF positivity in gastric cancer
Figure 4. Time to recurrence rates by qRT PCR positivity in gastric cancer
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Figure 5. Cancer specific survival rates by IF positivity in gastric cancer
Figure 6. Cancer specific survival rates by qRT PCR positivity in gastric
cancer
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At the multivariate analysis (Table 4), the stage at primary diagnosis
was found to be an independent risk factor in overall survival only,
while qRT-PCR resulted to be an independent risk factor in both
overall and disease free survival with hazard ratio of 31.3 and 18.5
respectively (p<0.05). IF was found to be a statistically significant
prognostic factor at univariate analysis (Figures 3 and 5), but it lost its
prognostic power at multivariate analysis (Table 4).
Table 4. Correlation between immunofluorescence evaluation,
cytologic examination and histopathological findings in colorectal
carcinoma.
Factor All
patient
s
IF
negativ
e
IF
positiv
e
P
valu
e
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No of patients 48 40
(83.3%)
8
(16.7%)
Age (years)
- mean ±  SD 69.5 ±
12.3
Gender
- Male
- Female
22
26
Histology
(differentiated/undifferentiate
d)
- G1
- G2
- G3
- G4
1
28
16
3
1
21
15
3
0
7
1
0
0.13
*
Depth of invasion
- T1
- T2
- T3
- T4
1
6
27
14
1
5
22
12
0
1
5
2
1*
Stage at primary diagnosis
- I
- II
- III
- IV
6
24
14
4
5
20
14
4
1
4
3
0
0.63
*
Cytologic examination
- negative
- positive
48
0
40
0
8
0
-
Colorectal Carcinoma
Global positivity rate for cytology, IF and qRT-PCR for FPTCs was
respectively 0%, 17% and 42%. Cytology was negative in all patients,
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including one patient with peritoneal carcinomatosis; this same
patient resulted positive for both CEA and CK20 at the qRT-PCR, but
negative at IF. As shown in Table 5, IF was found positive in similar
proportions in T2 (1/6 cases, 17%), T3 (5/27 cases, 19%) and T4
patients (2/14 cases, 14%). On the contrary of gastric carcinoma
cases, posititive IF was not related to grading, depth of invasion and
stage as shown in Table 5.
Table 5. Correlation between qRT-PCR analysis,
immunofluorescence evaluation and histopathological findings in
colorectal carcinoma.
Factor All
patient
s
qRT-
PCR
negativ
e
qRT-
PCR
positiv
e
P
value
No of patients 48 28
(58.3%)
20
(41.7%)
Age (years)
- mean ±  SD 69.5 ±
12.3
Gender
- Male
- Female
22
26
Histology
(differentiated/undifferentiate
d)
- G1
- G2
1
28
16
1
16
10
0
12
6
0.57*
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- G3
- G4
3 1 2
Depth of invasion
- T1
- T2
- T3
- T4
1
6
27
14
1
4
17
6
0
2
10
8
0.15*
Stage at primary diagnosis
- I
- II
- III
- IV
6
25
13
4
4
14
8
2
2
11
5
2
0.78*
Immunofluorescence
evaluation
- negative
- positive
40
8
27
1
13
7
0.006
^
In Table 6 are summarized the results for qRT-PCR: as well as the IF,
no correlation was found between qRT-PCR and grading, depth of
invasion and stage. Of the 8 patients who resulted positive to the IF,
7 of them were positive to qRT-PCR too, indicating a strong
correlation between IF and PCR in colorectal carcinoma (p=0.006).
Table 6.Multivariate Cox population hazards analysis for the gastric
cancer patients.
Progression-free survival Overall survival
P-
value
HR (95% CI) P-
value
HR (95% CI)
Depth of
invasion
T1-T3
T4
0.13 1
5.81 (0.56-59.7)
0.65 1
1.41 (0.31-6.29)
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Histology
G1-G2
G3-G4
0.28 1
0.15 (0.01-4.7)
0.14 1
0.04 (0.01-2.87)
Stage at
primary
diagnosis
I-II
III-IV
0.058 1
9.08 (0.92-89.5)
0.03 1
11.9 (1.20-
118.1)
IF evaluation
negative
positive 1 1
1 (0.20-4.95)
0.30 1
2.49 (0.43-14.2)
qRT-PCR
analysis
negative
positive
0.05 1
18.5 (0.70-490.4)
0.05 1
31.3 (0.65-
1494.7)
As shown in Figure 7, there was a higher positivity for CEA (42%)
respect to CK20 (10%). In addition, all patients positive for CK20 were
also positive for CEA.
Figure 7. Expression levels of CEA and CK20 mRNA in control subjects
and colorectal cancer patients. The cutoff values of CEA/GAPDH and
CK20/GAPDH was 0.66. The open circles show the alive patients. The
gray closed circles show patients who relapse. The black closed
circles show patients who died by tumor-relates causes.
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The analysis of survival was conducted on disease free survival only,
due to the few tumor-related deaths occurred during the follow-up.
Figured 8 and 9 shows the Kaplan-Meier survival curves for colorectal
carcinoma patients: at Log-rank test worse prognosis was
significantly associated to positive qRT-PCR (p=0.018) but not to IF
(p=0.88).
Figure 8. Time to recurrence rates by IF positivity in colorectal cancer
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Figure 9. Time to recurrence rates by qRT PCR positivity in colorectal
cancer
The multivariate Cox population analysis shows how qRT-PCR was
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found to be the only independent risk factor for relapse, with a
hazard ratio of 6,95 (p<0.05; table 7).
Table 7.Multivariate Cox population hazards analysis for the
colorectal cancer patients.
Progression-free survival
P-
value
HR (95% CI)
Depth of invasion
T1-T3
T4
0.09 1
4.84 (0.76-30.6)
Histology
G1-G2
G3-G4
0.31 1
0.41 (0.07-2.32)
Stage at primary
diagnosis
I-II
III-IV
0.17 1
3.23 (0.59-17.7)
IF evaluation
negative
positive 0.90 1
1.09 (0.18-6.46)
qRT-PCR analysis
negative
positive
0.05 1
6.95 (0.78-61.4)
Controls
All samples of peritoneal lavage from the control group resulted
negative for cytology, IF and real time qRT-PCR.
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DISCUSSION
Peritoneal cytology has been introduced by many institutions as
prognostic marker in both gastric and colorectal cancer. In gastric
cancer its importance has been increasing during the last years and it
has been proposed to use percutaneous or laparoscopic peritoneal
lavage in the preoperative staging of patients (21). Actually in some
cases positive peritoneal cytology from patients with gastric cancer is
being used as indication for neoadjuvant chemotherapy or as
absolute contraindication to surgery. It has been clearly assessed
from many studies its value as negative prognostic marker: although
positivity for peritoneal cytology increases with the stage of the
disease, it has been found from different studies how its prognostic
significance is independent. In fact, analyzing patients from the same
stage of disease, those with positive peritoneal cytology had worse
prognosis. The 7th TNM edition (Sobin LH, Gospodarowicz MK,
Wittekind C. International Union Against Cancer (UICC) TNM
classification of malignant tumours, 7th edition. New York: Wiley-
Liss; 2010) has given great importance to peritoneal cytology,
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including in the M1 group those patients with positive washings even
in absence of visible peritoneal implants.
In colorectal cancer the use of peritoneal cytology is less used and
standardized than in gastric cancer, probably for the minor incidence
of peritoneal carcinomatosis in this type of neoplasm. Most studies
on patients affected with colorectal cancer show that the detection
of single cancer cells in peritoneal cavity has prognostic relevance
(22-23), but in other cases results were different (24).
The primary problems with conventional peritoneal cytology are the
lack of sensitivity (positivity of 14-21% in gastric cancer and 0-11% in
colorectal cancer) and the high operator-dependent feature of this
test. In fact most of patients with positive peritoneal lavage develop
peritoneal carcinomatosis, but it is even developed by many of the
patients with negative peritoneal washing. Since the knowledge
about the presence of isolated tumor cells in the peritoneal cavity
has been growing in importance for the treatment strategy in both
gastric and colorectal cancer, clinicians need new and more sensitive
and specific techniques to retrieve these new prognostic factors. The
simplest technique that gives little advantage on the results of
traditional cytopathology is to integrate it with immunocytochemical
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methods, using monoclonal antibodies directed to gastric cancer-
associated antigens (10).
Kodera et al. (16) proposed the use of real time qRT-PCR for the
detection of free peritoneal tumor cells from patients affected with
gastric cancer: a greater sensitivity of real time qRT-PCR was reported
in comparison with cytology: all patients who presented peritoneal
carcinomatosis during the follow up period were positive at time of
surgery for real time qRT-PCR on peritoneal washes and omentum
while only about 30% of them were positive even for conventional
cytology.
After 1998 some more Authors, mostly Japanese, reported about the
use of real time qRT-PCR for the detection of isolated peritoneal
tumor cells from gastric cancer patients and all of them concluded
confirming how real time qRT-PCR is a more specific and sensitive
technique than cytopathology and that it was found to be as
independent prognostic marker. Similar studies about colorectal
cancer are also present in the literature, but less frequently. In their
study Guller et al. (25) report  that, on a total of 39 colorectal cancer
patients, 10 of them resulted positive for the RT-PCR (CEA and CK20)
at the peritoneal lavage. During the follow up period 8 of them had
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recurrence and positive peritoneal real time qRT-PCR was found to
be an independent prognostic factor.
Hara et al. (26) published the first and only study comparing the
results of RT-PCR on peritoneal lavage in gastric and colorectal cancer
patients. They found that prognosis in positive RT-PCR patients was
worse in both colorectal and gastric cancer; they also found that,
among real time qRT-PCR positive cases, peritoneal carcinomatosis
was significantly more frequent in gastric cancer patients but not in
colorectal patients. They concluded stating that colorectal carcinoma
cells must have some biological characteristics that make them with a
low-peritoneal metastatic potential.
Some criticism have been moved to this molecular technique, since
some Authors believe that the expression of some genes used for the
identification of tumor cells may be present in inflammatory cells as
well,  resulting real time qRT-PCR in a high sensitivity and low
specificity test (19).
Some problems about the optimization of the molecular techniques
still have to be debated: for example, the possibility of high rate of
false positive diagnosis at RT-PCR. This can be due to an illegitimate
expression of marker genes in noncancerous cells (27) or to a too
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high sensitivity of the technique that can even detect mRNA markers
from a very small, clinically insignificant, number of cells.
Nevertheless in some Japanese Institutions real time qRT-PCR is
already used in the clinical practice: patients with negative cytology
and positive real time qRT-PCR at preoperative staging laparoscopy
are treated with a short-term intraperitoneal chemotherapy (28).
To our knowledge nothing is reported about the use of IF for the
detection of free peritoneal cancer cells in enriched samples of
peritoneal lavages. Our study combined for the first time the use of
real time qRT-PCR with IF and immunomagnetic enrichment of
epithelial cells to detect free peritoneal tumor cells in gastric and
colorectal cancer. For each technique we used two different markers:
CEA and CK20 for the qRT-PCR and CEA and EpCAM for IF. Our results
confirmed the low sensitivity of the traditional cytology: in fact, it
was positive only in four cases of gastric cancer with associated
massive peritoneal carcinomatosis and in none of colorectal cancers.
All cytological positive samples resulted positive also for IF and real
time qRT-PCR. On the contrary, no false positive were found at the
qRT-PCR or IF examination in the group of patients with non-
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malignant diseases, further demonstrating the validity of our
procedure.
In comparison with cytology, both IF and real time qRT-PCR showed
higher positivity rates, being 15% and 78% for gastric cancer patients
and 17% and 42% for colorectal cancer patients respectively. Among
the gastric cancer patients, IF was positive not only in the 3 of them
with massive carcinomatosis, but also in 1 case with minor extent of
peritoneal dissemination. Interestingly, in colorectal cancer patients
we found positivity even in early stages of disease.
The positivity rate for qRT-PCR in gastric cancer patients was
impressive, comprising more than 3/4 of the patients, distributed in
all T1-T4 stages of disease. In contrast, in colorectal cancer patients
the qRT-PCR positivity was found in less than half of patients, most of
them with T3-T4 disease. All patients positive at IF were also positive
at qRT-PCR, except for one colon cancer and one gastric cancer
patients.
Our data showed how positive IF resulted to be significantly
associated to grading, depth of invasion, stage of disease and
cytology in gastric cancer. On the opposite for colorectal cancer IF
was note related to any of the examined clinicopathological factors.
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In the survival study positive IF was associated to worse overall and
disease free survival in gastric patients at the univariate analysis; at
the multivariate analysis IF was not found to be an independent
prognostic factor in gastric cancer patients. In colorectal cancer cases
IF was not a statistically significant prognostic factor in both
univariate and multivariate analysis.
RT-PCR positivity was associated to higher grading in gastric cancer
and only to positive IF in colorectal cancer. In both gastric and
colorectal cancer RT-PCR was found to be one of the strongest
independent prognostic factors.
From these data we can notice that IF seems to be associated to the
most common clinicopathological factors in GC, but it has no
prognostic value in both gastric and colorectal cancer patients. On
the other hand RT-PCR is not frequently associated to other
clinicopathological factors but resulted to be independently relevant
for the prognosis in both gastric and colorectal cancer.
In conclusion, we believe that the combination of conventional real
time qRT-PCR with immunoenrichment and IF, which permit
morphological assessment and unequivocal identification of the
FPTCs as well as validation of the molecular analysis, could be an
58
useful and more powerful procedure for the detection of free
peritoneal tumor cells. More studies on these cells are requested to
understand their prognostic power and any other possible clinical
application. Since the treatment of cancer is going toward the
personalized therapy, as well as for the circulating tumor cells, in the
future the characterization of peritoneal tumor cells may be
interrogated to guide molecularly targeted therapies, assess
treatment effect and detect development of drug resistance.
59
REFERENCES
 A. Gervasoni, R. M. Monasterio Munoz, G.S. Wengler, A. Rizzi, A. Zaniboni,
O. Parolini. Molecular signature detection of circulating tumor cells using
a panel of selected genes. Cancer letters 2008; 263:267-279.
 Abe N, Watanabe T, Toda H, Machida H, Suzuki K, Masaki T et al.
Prognostic significance of carcinoembryonic antigen levels in peritoneal
washes in patients with gastric cancer. Am J Surg 2001;181:356-61.
 Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B,
Jackson DE, Roh M and Hohn D (1991) Resectable gastric carcinoma. An
evaluation of preoperative and postoperative chemotherapy. Cancer 68,
1501-1506.
 Asao T, Fukuda T, Yazawa S, Nagamachi Y. CEA levels in peritoneal
washings from gastric cancer patients as a prognostic guide. Cancer Lett
1989;47:79-81.
 Baba h, Korenaga D, Okamura T., Saito A and Sugimachi K. Prognostic
factors in gastric cancer with serosal invasion. Arch Surg 1989; 124:1061-
1064.
 Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for
cytological examination in 1297 patients with gastric carcinoma. Am J
Surg 1999; 178: 256-262.
 Benevolo M, Mottolese M, Cosimelli M, et al. Diagnostic and prognostic
value of peritoneal immunocytology in gastric cancer. J Clin Oncol 1998;
16: 3406-3411.
 Boku T, Nakane Y, Minoura T, Takada H, Yamamura M, Hioki K et al.
Prognostic significance of serosal invasion and free intraperitoneal cancer
cells in gastric cancer. Br J Surg 1990;77:436-9.
 Bold RJ, Ota DM, Ajani JA, et al. Peritoneal and serum tumor markers
predict recurrence and survival of patients with resectable gastric cancer.
Gastric Cancer 1999;2:1-7.
60
 Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of
positive cytology findings from abdominal washings in patients with
gastric cancer. Br J Surg 1996;83:672-4.
 Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, Selby P.
Detection of epithelial cancer cells in peripheral blood by reverse
transcriptase-polymerase chain reaction. Br J Cancer 1995;71:278-81.
 Cetin B, Atalay C, Aslan S, Babacan B, Hatipoglu C, Akinci M et al.
Peritoneal carcinoembryonic antigen level for predicting locoregional and
distant spread of gastric cancer. Surg Today 2005;35:919-24.
 Chu DZ, Lang NP, Thompson C, Osteen PK and Westbrook KC (1989)
Peritoneal carcinomatosis in nongynecologic malignancy. A prospective
study of prognostic factor. Cancer 63, 364-367.
 Fujimura T, Ohta T, Kitagawa H, Mori T, Ishii T, Niwa H et al. Trypsinogen
expression and early detection for peritoneal dissemination in gastric
cancer. J Surg Oncol 1998;69:71-5.
 Fujiwara Y, Doki Y, Taniguchi H, Sohma I, Takiguchi S, Miyata H et al.
Genetic detection of free cancer cells in the peritoneal cavity of the
patient with gastric cancer: present status and future perspectives.
Gastric Cancer 2007;10:197-204.
 Goeminne JC, Guillaume T, Salmon M, Machiels JP, D’Hondt V, Symann M.
Unreliability of carcinoembryonic antigen (CEA) reverse transcriptase-
polymerase chain reaction (RT-PCR) in detecting contaminating breast
cancer cells in peripheral blood stem cells due to induction of CEA by
growth factors. Bone Marrow Transplant 1999;24:769-75.
 Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as
detected by real-time quantitative polymerase chain reaction represent a
prognostic factor in patients undergoing surgery for colorectal cancer.
Ann Surg. 2002; 236:768-75.
 Gunderson LL and Sosin H (1982) Adenocarcinoma of the stomach: Areas
of failure in a reoperation series (second or symptomatic look), clinico-
61
pathologic correlation and implications for adjuvant therapy. Int J Radiat
Biol Phys 8, 1-11.
 Hagiwara A, Takahashi T, Kojima O, et al. Prophylaxis with carbon
adsorbed mitomycin against peritoneal recurrence of gastric cancer.
Lancet 1992;339:629-631.
 Hara M, Nakanishi H, Jun Q, et al. Comparative analysis of intraperitoneal
minimal free cancer cells between colorectal and gastric cancer patients
using quantitative RT-PCR: possible reason for rare peritoneal recurrence
in colorectal cancer. Clin. Exp. Metastasis. 2007; 24:179-89.
 Hayes N, Wayman J, Wadehra V, Schott DJ, Raimes SA, Griffin SM,.
Peritoneal cytology in the surgical evaluation of gastric carcinoma. Br. J
Cancer 1999;79:520-4
 Homma Y, Ushida S, Yamada M, Kobayashi H, Suzuki K. Positive peritoneal
washing cytology in multiple cavities can predict poor prognosis of
advanced gastric cancer patients. Ann Surg Oncol 2010;17:455-60.
 Japanese Research Society for Gastric Cancer. Japanese classification of
gastric carcinoma. 2nd English ed. Gastric Cancer 1998;1:11-24.
 Jayne DG, Fook S, Loi C and Seow-Choen F (2002) Peritoneal
carcinomatosis from colorectal cancer. Br J Surg 89, 1545-1550.
 Juhl H, Stritzel M, Wroblewski A, Henne-Bruns D, et al. Immunocytological
detection of micrometastatic cells: comparative evaluation of findings in
the peritoneal cavity and the bone marrow of gastric, colorectal and
pancreatic cancer patients. Int J Cancer 1994; 57: 330-335.
 Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K.
Prognostic impact of PCR-based identification of isolated tumour cells in
the peritoneal lavage fluid of gastric cancer patients who underwent a
curative R0 resection. Br J Cancer. 2007; 97:550-6.
 Khair G., Monson. J.R., Greenman J. Epithelial molecular markers in the
peripheral blood of patients with colorectal cancer. Dis. Colon Rectum 50
2007;1188-1203.
62
 Kodera Y, Nakanishi H, Ito S, et al. Quantitative detection of disseminated
free cancer cells in peritoneal washes with real-time reverse transcriptase-
polymerase chain reaction: a sensitive predictor of outcome for patients
with gastric carcinoma. Ann Surg 2002; 235: 499-506.
 Kodera Y, Nakanishi H, Ito S, Mochizuki Y, Ohashi N, Yamamura Y et al.
Prognostic significance of intraperitoneal cancer cells in gastric
carcinoma: analysis of real time reverse transcriptase-polymerase chain
reaction after 5 years of followup. J Am Coll Surg 2006;202:231-6.
 Kodera Y, Nakanishi H, Yamamura Y, et al. Prognostic value and clinical
implications of disseminated cancer cells in the peritoneal cavity detected
by reverse transcriptase-polymerase chain reaction and cytology. Int J
Cancer. 1998;79:429-33.
 Kodera Y, Yamamura Y, Shimizu Y, et al. Peritoneal washing cytology:
prognostic value of positive findings in patients with gastric carcinoma
undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60-64;
discussion 64-65.
 Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A and Wakatsuki T
(1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by
continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer
61, 232-237.
 Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Hiraoka H. Prognostic
significance of intraperitoneal free cancer cells in gastric cancer patients. J
Cancer Res Clin Oncol 1984;108:236-8.
 Kowalewska M, Chechlicska M, Markowicz S, Kober P, Nowak R. The
relevance of RT-PCR detection of disseminated tumour cells is hampered
by the expression of markers regarded as tumour-specific in activated
lymphocytes. Eur J Cancer 2006;42:2671-4.
 Kowalewska M, Chechlinska M, Nowak R. Carcinoembryonic antigen and
cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what
we are detecting by mRNA examination?. Br J Cancer. 2008;98:512-3.
63
 La Torre M, Ferri M, Giovagnoli MR, Sforza N, Cosenza G, Giarnieri E,
Ziparo V. Peritoneal wash cytology in gastric carcinoma. Prognostic
significance and therapeutic consequences. Eur J Surg Oncol. 2010;
36:982-6.
 Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F and Sullinger J
(1990) Patterns of failure following curative resection of gastric
carcinoma. Int J Radiat Biol Phys 19, 1357-1362.
 Li JK, Zheng M, Miao CW Zhang JH, Ding GH, Wu WS. Peritoneal lavage
cytology and carcinoembryonic antigen determination in predicting
peritoneal metastasis and prognosis of gastric cancer. World J
Gastroenterol 2005;11:7374-7.
 Moertel CG, Rleming TR, MacDonald JS, et al. Levamisole and fluorouracil
for adjuvant therapy of resected colon carcinoma. N Engl J Med
1990;322:352-358.
 Mori N, Oka M, Hazama S, Iizuka N, Yamamoto K, Yoshino S et al.
Detection of telomerase activity in peritoneal lavage fluid from patients
with gastric cancer using immunomagnetic beads. Br J Cancer
2000;83:1026-32.
 Mori T, Fujiwara Y, Sugita Y, Azama T, Ishii T, Taniguchi K et al.
Application of molecular diagnosis for detection of peritoneal
micrometastasis and evaluation of preoperative chemotherapy in
advanced gastric carcinoma. Ann Surg Oncol 2004;11:14-20.
 Nakanishi H, Kodera Y, Torii A, Hirai T, Yamamura Y, Kato T et al.
Detection of carcinoembryonic antigen-expressing free tumor cells in
peritoneal washes from patients with gastric carcinoma by polymerase
chain reaction. Jpn J Cancer Res 1997;88:687-92.
 Nekarda H, Gess C, Stark M, Mueller JD, Fink U, Schenck U et al.
Immunocytochemically detected free peritoneal tumour cells (FPTC) are a
strong prognostic factor in gastric carcinoma. Br J Cancer 1999;79:611-9.
64
 Noura S, Ohue M, Seki Y, Yano M, Ishikawa O, Kameyama M. Long-term
prognostic value of conventional peritoneal lavage cytology in patients
undergoing curative colorectal cancer resection. Dis Colon Rectum.
2009;52:1312-20.
 Oyama K, Terashima M, Takagane A, Maesawa C. Prognostic significance
of peritoneal minimal residual disease in gastric cancer detected by
reverse transcription-polymerase chain reaction. Br J Surg 2004; 19: 435-
43.
 Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and
specific biological properties of disseminating tumour cells. Nat Rev
Cancer. 2008 May;8(5):329-40.
 Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, Meyer J,
Meyer HJ and Buente H (1989) Phase II study with the combination of
etoposide, doxorubicin and cisplatin in advanced measurable gastric
cancer. J Clin Oncol 7, 1310-1317.
 Ribeiro U Jr, Gama-Rodrigues JJ, Bitelman B, Ibrahim RE, Safatle-Ribeiro
AV, Laudanna AA et al. Value of peritoneal lavage cytology during
laparoscopic staging of patients with gastric carcinoma. Surg Laparosc
Endosc 1998;8:132-5.
 Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J,
Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois
Y, Vignal J and Gilly FN (2000) Peritoneal carcinomatosis from non-
gynecologic malignancies: results of the EVOCAPE 1 multicentric
prospective study. Cancer 88, 358-363.
 Sakakura C, Takemura M, Hagiwara A, Shimomura K, Miyagawa K,
Nakashima S et al. Overexpression of dopa decarboxylase in peritoneal
dissemination of gastric cancer and its potential as a novel marker for the
detection of peritoneal micrometastases with real-time RT-PCR. Br J
Cancer 2004 9;90:665-71.
65
 Schoenfeld A, Luqmani Y, Smith D, O’Reilly S, Shousha S, Sinnett HD et al.
Detection of breast cancer micrometastases in axillary lymph nodes by
using polymerase chain reaction. Cancer Res 1994 1;54:2986-90.
 Schott A, Vogel I, Krueger U, et al. Isolated tumor cells are frequently
detectable in the peritoneal cavity of gastric and colorectal cancer
patients and serve as a new prognostic marker. Ann. Surg. 1998;.
227:372-9.
 Shimomura K, Sakakura C, Takemura M, Takagi T, Fukuda K, Kin S et al.
Combination of L-3-phosphoserine phosphatase and CEA using real-time
RT-PCR improves accuracy in detection of peritoneal micrometastasis of
gastric cancer. Anticancer Res 2004;24(2C):1113-20.
 Sugarbaker PH (2004) Carcinomatosis from gastrointestinal cancer. Ann
Med 36, 9-22.
 Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE,
Oliff L and Schlag P (1990) Early postoperative intraperitoneal
chemotherapy as an adjuvant therapy to surgery for peritoneal
carcinomatosis from gastrointestinal cancer: pharmacological studies.
Cancer Res 50, 5790-5794.
 Sugita Y, Fujiwara Y, Taniguchi H, et al. Quantitative molecular diagnosis
of peritoneal lavage fluid for prediction of peritoneal recurrence in gastric
cancer. Int J Oncol 2003;23:1419-23.
 Suzuki T, Ochiai T, Hayashi H, Hori S, Shimada H, Isono K. Peritoneal
lavage cytology findings as prognostic factor for gastric cancer. Semin
Surg Oncol 1999;17:103-7.
 Vogel P, Rüschoff J, Kümmel S, Zirngibl H, Hofstädter F, Hohenberger W et
al. Immunocytology improves prognostic impact of peritoneal tumour cell
detection compared to conventional cytology in gastric cancer. Eur J Surg
Oncol 1999;25:515-9.
 Wang JY, Lin SR, Lu CY, Chen CC, Wu DC, Chai CY et al. Gastric cancer cell
detection in peritoneal lavage: RT-PCR for carcinoembryonic antigen
66
transcripts versus the combined cytology with peritoneal
carcinoembryonic antigen levels. Cancer Lett 2005;223:129-35
 Wang Z, Zhang X, Xu H, Zhou X, Jiang L, Lu C. Detection of peritoneal
micrometastasis by reverse transcriptase-polymerase chain reaction for
heparanase mRNA and cytology in peritoneal wash samples. J Surg Oncol
2005;90:59-65.
 Wind P, Norklinger B, Roger V, Kahlil A, Guin E, Parc R. Long-term
prognostic value of positive peritoneal washing in colon cancer. Scand. J.
Gastroenterol. 1999; 34:606-10.
 Wisbeck WM, Beecher EM and Russell AH (1986) Adenocarcinoma of the
stomach: Autopsy observations with therapeutic implications for the
radiation oncologist. Radiother Oncol 7, 13-18.
 Wu CC, Chen JT, Chang MC, et al. Optimal surgical strategy for potentially
curable serosa-involved gastric carcinoma with intraperitoneal free cancer
cells. J Am Coll Surg 1997; 184: 611-617.
 Yamamoto M, Baba H, Kakeji Y, Endo K, Ikeda Y, Toh Y et al. Prognostic
significance of tumor markers in peritoneal lavage in advanced gastric
cancer. Oncology 2004;67:19-26.
 Yonemura Y, Fujimura T, Ninomiya I, Kim BS, Bandou E, Sawa T et al.
Prediction of peritoneal micrometastasis by peritoneal lavaged cytology
and reverse transcriptase-polymerase chain reaction for matrix
metalloproteinase-7 mRNA. Clin Cancer Res 2001;7:1647-53.
 Yoo CH, Noh SH, Shin DW, Choi SH and Min JS (2000) Recurrence following
curative resection for gastric carcinoma. Br J Surg 87, 236-242.
